ABC | Volume 112, Nº4, Abril 2019

Artigo Original Yang Li Fatores de risco para complicações do PTSMA Arq Bras Cardiol. 2019; 112(4):432-438 1. Kimura A. Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: the cause of dilated cardiomyopathy: genetic or acquired? (genetic-side). Circ J. 2011;75(7):1756-65. 2. Parry DJ, Raskin RE, Poynter JA, Ribero IB, Bajona P , Rakowski H, et al. Short andmedium termoutcomes of surgery for patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2015;99(4):1213-9. 3. Efthimiadis GK, Pitsis A, Pagourelias ED, Kamperidis V , Kelpis T , Meditskou S, et al. Surgical septal myectomy for hypertrophic cardiomyopathy inGreece: a single-center initial experience. Hellenic J Cardiol. 2014;55(2):132-8. 4. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2011;75(1):28-37. 5. Butz T , Horstkotte D , Koerfer J, Langer C, Seggewiss H, Faber L. Assessment of myocardial scarring by contrast enhanced magnetic resonance imaging in a patient 11 years after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2010;145(1):e3-5. 6. JensenMK, HavndrupO , Hassager C, Helqvist S, Kelbaek H, Jorgensen E, et al. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy. Scand Cardiovasc J. 2011;45(3):153-60. 7. Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4(3):256-65. 8. Chikkabasavaiah NA, Puttegowda B, Panneerselvam A, Ananthakrishna R, Kapanigowda AP , Basavappa R. Remote infarction following percutaneous transluminal septal myocardial ablation: a report of two cases. Cardiovasc Interv Ther. 2011;26(2):142-6. 9. Nemes A, Balázs E, Soliman OI, Sepp R, Csanády M, Forster T . Long- term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results fromSZEGED study. Heart Vessels. 2009;24(5):352-6. 10. Gersh BJ , Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery,AmericanSocietyofEchocardiography,AmericanSocietyofNuclear Cardiology, Heart Failure Society of America, Heart RhythmSociety, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60. 11. Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;114(9):1383-9. 12. Rosella LC, Lebenbaum M, Fitzpatrick T , Zuk A, Booth GL. Prevalence of Prediabetes and Undiagnosed Diabetes in Canada (2007-2011) According to Fasting Plasma Glucose and HbA1c Screening Criteria. Diabetes Care. 2015;38(7):1299-305. 13. Moon J, Cho IJ , ShimCY, Ha JW , Jang Y , ChungN, et al. Abnormal myocardial capillary density in apical hypertrophic cardiomyopathy can be assessed by myocardial contrast echocardiography. Circ J. 2010;74(10):2166-72. 14. Madsen LH, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B, et al. Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation. Cardiology. 2009;114(3):167-73. 15. Gomes OM, Coelho AA, Osterne EC, Abrantes RD. Coronary morphology and conduction system disturbance induced by therapeutic embolization of the coronary septal artery. Heart Surg Forum. 2010;13(1):E45-8. 16. Faber L, Welge D , Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119(2):163-7. 17. El-Jack SS, Nasif M, Blake JW, Dixon SR, Grines CL, O’Neill WW . Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20(1):73-6. 18. van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van DomburgRT , et al.Usefulnessof clinical,echocardiographic, andprocedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101(9):1315-20. 19. Veselka J,ZemánekD, TomasovP , DuchonováR, LinhartováK. Alcoholseptal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009;24(1):27-31. 20. Gersh BJ, Maron BJ, Bonow RO , Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24): 2761-96. 21. Qiao SB, Yuan JS. How to improve the safety of percutaneous transluminal septal myocardial ablation. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(3):193-5. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 438